Skip to content

Microbot Medical MBOT Issuance Costs Not Paid

Issuance Costs Not Paid at other companies

CG Oncology logo
CG OncologyCGON
$139K-35.3%
Beyond Meat logo
Beyond MeatBYND
$46.75K
Dogwood Therapeutics logo
Dogwood TherapeuticsDWTX
$26.57K
BRC logo
BRCBRCC
$0-100%
Precigen logo
PrecigenPGEN
$0-100%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$92.75K

Other financials

Income statement

See full
Revenue$105.0K
Gross profit$2.0K
Operating income-$4.3M-43.0%
Net income-$3.7M-41.1%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$3.7M+13.7%
Total debt$898.0K+551%
Total equity$74.1M+156%
Total assets$78.1M+153%

Cash flow

See full
Operating cash flow-$5.1M-75.8%
CapEx$108.0K+731%
Free cash flow-$5.2M-78.8%

Valuation

See full
Market cap$128.28M+36.1%
Enterprise value$125.53M+39.0%
P/S674.3×

Profitability

See full
Operating margin25,292.9%
Net margin-3,669.9%
FCF margin-852.8%

Returns & leverage

See full
Return on equity-27.6%-10.2pp
Debt / equity0.0×
Current ratio22.6×+6.4×

Where this comes from

Reported directly by Microbot Medical in its filing.

Tagged under the XBRL concept MBOT:IssuanceCostsNotPaid.

The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Microbot Medical's issuance costs not paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Microbot Medical's issuance costs not paid?
Microbot Medical (MBOT) reported issuance costs not paid of $10K in Q1 2025.
What does issuance costs not paid mean?
This metric tracks the portion of costs associated with issuing equity or debt that have been incurred but not yet settled in cash. It represents a short-term liability that will eventually impact future cash flows. Tracking this provides visibility into the true cost of capital raising activities that are not immediately reflected in cash outflows.